Cart
sales@molnova.com
HCV-IN-30
CAS No. 1007882-23-6
HCV-IN-30( —— )
Catalog No. M26246 CAS No. 1007882-23-6
HCV-IN-30 is an HCV NS5A replication complex inhibitor (IC50s: 901 and 102 nM for genotypes 1a and 1b replicons).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 25MG | 36 | In Stock |
|
| 50MG | 54 | In Stock |
|
| 100MG | 87 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 230 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHCV-IN-30
-
NoteResearch use only, not for human use.
-
Brief DescriptionHCV-IN-30 is an HCV NS5A replication complex inhibitor (IC50s: 901 and 102 nM for genotypes 1a and 1b replicons).
-
DescriptionHCV-IN-30 is an HCV NS5A replication complex inhibitor (IC50s: 901 and 102 nM for genotypes 1a and 1b replicons).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorCDK1/CyclinB| Cdk5/p25| GSK-3β
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1007882-23-6
-
Formula Weight624.77
-
Molecular FormulaC36H44N6O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 20 mg/mL (32.01 mMul)
-
SMILESO=C(N1[C@H](C2=NC=C(C3=CC=C(C4=CC=C(C5=CN=C([C@H](CCC6)N6C(OC(C)(C)C)=O)N5)C=C4)C=C3)N2)CCC1)OC(C)(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Leclerc S, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem. 2001 Jan 5;276(1):251-60.
molnova catalog
related products
-
Herpes Virus Inhibit...
Herpes Virus Inhibitor 1
-
15-Deoxypulic acid
15-Deoxypulic acid is a natural product of Pulicaria, Asteraceae. 15-Deoxypulic acid can be used as a reference standard.
-
Neuromedin S (rat)
Potent, endogenous neuromedin U receptor agonist (EC50 values are 65 and 91 pM at NMU1 and NMU2 respectively). Induces phase shifts in the circadian rhythm of locomotor activity following i.c.v. administration. Potent endogenous anorexigenic peptide.
